8-K: Current report filing
Published on February 10, 2005
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
Date of report (date of earliest event reported): February 9, 2005
COMMONWEALTH BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Virginia | 001-13467 | 56-1641133 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
601 Biotech Drive
Richmond, Virginia 23235
(Address of principal executive offices)
Registrants telephone number, including area code: (804) 648-3820
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
On February 9, 2005, Commonwealth Biotechnologies, Inc. (CBI) entered into a certain Amended and Restated Employment Agreement with Thomas R. Reynolds, Executive Vice President, Science & Technology and Secretary of CBI (the Revised Agreement). The Revised Agreement is effective as of January 1, 2005 and amends and restates that certain Employment Agreement, dated June 25, 1997 by and between CBI and Mr. Reynolds. The Revised Agreement has a term of three years and provides for a base salary of at least $190,000, which may be adjusted from time to time at the discretion of CBI. In connection with the execution of the Revised Agreement, CBI issued to Mr. Reynolds incentive stock options to purchase up to 30,000 shares of CBIs common stock. In addition, the Revised Agreement provides that Mr. Reynolds is eligible to receive (a) an annual cash bonus of up to $25,000, (b) an annual grant of incentive stock options to purchase up to 5,000 shares of CBI Common Stock and (c) an annual grant of up to 5,000 restricted shares of CBI common stock (collectively, the Bonus Compensation). The amount of Bonus Compensation that CBI shall issue to Mr. Reynolds on an annual basis shall be based upon CBIs financial performance and calculated in accordance with specific formulae included in the Revised Agreement.
Under the Revised Agreement, the Company may terminate Mr. Reynolds employment at any time for Cause as such term is defined in the Revised Agreement, without incurring any continuing obligations to Mr. Reynolds. If the Company terminates Mr. Reynolds employment for any reason other than for Cause or if Mr. Reynolds terminates his employment for Good Reason (as such terms are defined in the Revised Agreement), the Company will remain obligated to continue to provide the compensation and benefits specified in the Revised Agreement for a period of twelve months following the date of termination. To the extent CBI experiences a Change-of-Control (as such term is defined in the Revised Agreement), Mr. Reynolds may deem the Revised Agreement to be terminated without Cause. Under such circumstances, Mr. Reynolds would be eligible to receive the compensation and benefits specified in the second sentence of this paragraph. In addition, in the event of a Change-of-Control, all unvested options and restricted shares of CBI common stock held by Mr. Reynolds shall immediately vest. To the extent CBI undergoes a Change-of-Control during the last year of the term of the Revised Agreement, Mr. Reynolds shall have the option of receiving the Non-Renewal Benefits (as defined below) in lieu of the salary and benefits described above.
To the extent CBI has not offered to renew the Revised Agreement or enter into a similar arrangement with Mr. Reynolds on or before January 1, 2007, Mr. Reynolds may declare CBI in breach and terminate the Revised Agreement. In such circumstances, CBI shall continue to pay Mr. Reynolds salary and benefits under the Revised Agreement for the period beginning on the date of such termination and ending on December 31st of the year following the date of termination (collectively, the Non-Renewal Benefits).
The Revised Agreement contains a non-competition provision, which prohibits Mr. Reynolds from competing with the Company or soliciting its employees under certain circumstances. A court may, however, determine that these non-competition provisions are unenforceable or only partially enforceable.
2
ITEM 1.02 TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT.
As of the effective date of the Reynolds Employment Agreement, CBI and Mr. Reynolds terminated that certain Executive Severance Agreement, dated as of June 25, 1997, in accordance with its terms.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(a) | Financial statements of businesses acquired. |
Not Applicable.
(b) | Pro forma financial information. |
Not Applicable.
(c) | Exhibits. |
99.1 | First Amended and Restated Employment Agreement by and between Thomas R. Reynolds and Commonwealth Biotechnologies, Inc., dated February 9, 2005 and effective as of January 1, 2005. |
3
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
COMMONWEALTH BIOTECHNOLOGIES, INC. |
||
By: |
/s/ Robert B. Harris, Ph.D. |
|
Robert B. Harris, Ph.D. |
||
President and Chief Executive Officer |
Dated: February 10, 2005
4
EXHIBIT INDEX
Number |
Description of Exhibit |
|
99.1 | First Amended and Restated Employment Agreement by and between Thomas R. Reynolds and Commonwealth Biotechnologies, Inc., dated February 9, 2005 and effective as of January 1, 2005. |
5